Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML

NCT06757855 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

29

Enrollment

OTHER

Sponsor class

Conditions

CML,Blast Phase

Interventions

DRUG: Olverembatinib
DRUG: Venetoclax
DRUG: Azacitidine

Sponsor

Institute of Hematology & Blood Diseases Hospital, China